Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
1J5.SI
Strong BuyFLAGHyphens Pharma International Limited · Healthcare · Singapore · $87M · Avg Vol: $56K/d
100
StockRankGet insider-trade alerts
Q
77
V
84
M
73
P/E (TTM)
12.0x
ROE
13.0%
D/E
0.2x
Dividend %
4.1%
AI CONVICTION THESIS
Hyphens Pharma has defensive characteristics and recent insider support, but the market cap is small ($111M), limiting liquidity for a global fund. While the business model is solid, the thesis lacks the dramatic macro tailwind needed to justify high-conviction status over larger, more liquid compounders.
Loading 1Y...
PRICE (1Y)+0.0%
SMA 50SMA 200
Close
$0.2785
RSI (14)
30.0
52W High
$0.3021
From 52W High
0.9%
SCORE BREAKDOWN
Quality
77
ROIC
11.2%77.0
ROE
13.0%78.7
GP/Assets
58.7%90.8
Op. Margin
7.9%60.1
FCF/Assets
14.2%92.2
Piotroski
497.9
Int. Cover
16.5x69.4
D/E Ratio
0.17x54.4
Current Ratio
1.86x35.7
Value
84
P/E (TTM)
12.0x83.0
EV/EBITDA
6.4x87.1
P/FCF
6.4x90.6
P/B
1.7x67.7
P/S
0.6x90.2
Div Yield
4.1%83.9
Momentum
73
52W High %
92%87.0
RS 6M
-3%60.9
SMA 50/200
1.07x73.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+46%53.1
Q Growth
159%89.6
FUNDAMENTALS
Market Cap
$87M
P/E (Forward)
8.2x
Gross Margin
41.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1J5.SI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1J5.SI | Hyphens Pharma International Limited(you) | $87M | 100 | Strong Buy |
| 5WA.SI | OUE Healthcare Limited | $168M | 88 | Strong Buy |
| ULG.SI | UltraGreen.ai Limited | $843M | 92 | Strong Buy |
| AP4.SI | Riverstone Holdings Limited | $950M | 94 | Strong Buy |
| 1D4.SI | Aoxin Q & M Dental Group Limited | $196M | 43 | Hold |
| QC7.SI | Q & M Dental Group (Singapore) Limited | $410M | 52 | Hold |
| BSL.SI | Raffles Medical Group Ltd | $1.3B | 72 | Buy |
| FHH.SI | Foundation Healthcare Holdings Limited | $747M | 59 | Hold |
| 42C.SI | iX Biopharma Ltd. | $361M | 27 | Sell |
| BMGL | Basel Medical Group Ltd | $122M | 3 | Strong Sell |
Peer medians: ROE 1.2% · P/E 21.4x · Gross margin 43.9%